University of Erlangen-Nürnberg Medical School
fau.deLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
272
Active
47
Phase 3
43
Total enrollment
55,962
Pipeline matrix
Showing 8 of 8 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dapagliflozin 10mg Tab | — | — | — | — | — | 1 | |
| Three intra-articular hyaluronic acid (HA) injections | — | — | — | — | — | 1 | |
| One intra-articular hyaluronic acid (HA) | — | — | — | — | — | 1 | |
| SP16-3M | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Additional interventional telemedical management | — | — | — | — | — | 1 | |
| Chemotherapy 5-Fluorouracil | — | — | — | — | — | 1 | |
| Chemotherapy Cisplatin | — | — | — | — | — | 1 |
Next readouts
- 2026-04-30
- 2026-08-01
- 2026-10-31
- 2029-05
- 2094-12-31
- 2098-12-31
Top conditions
- Hypertension10
- Ulcerative Colitis10
- Cancer8
- Metabolic Syndrome7
- Inflammatory Bowel Diseases6
- Osteopenia5
- Cancer Cachexia5
- Rheumatoid Arthritis5
Frequently asked questions about University of Erlangen-Nürnberg Medical School
- How many clinical trials does University of Erlangen-Nürnberg Medical School have on ClinicalTrials.gov?
- University of Erlangen-Nürnberg Medical School is listed as the lead sponsor on 272 clinical trials in ClinicalTrials.gov, 47 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Erlangen-Nürnberg Medical School's trials are in Phase 3?
- 43 of University of Erlangen-Nürnberg Medical School's trials are in Phase 3, spread across 8 active drug programs.
- What therapeutic areas does University of Erlangen-Nürnberg Medical School focus on?
- University of Erlangen-Nürnberg Medical School's most-studied conditions on ClinicalTrials.gov are Hypertension, Ulcerative Colitis, Cancer, Metabolic Syndrome, Inflammatory Bowel Diseases.
- When are University of Erlangen-Nürnberg Medical School's next clinical trial readouts?
- University of Erlangen-Nürnberg Medical School has 6 upcoming primary-completion readouts tracked here; the soonest is “The smartNTx Trial:Telemedical Management Versus Standard Aftercare in Kidney Transplant Recipients (KTR)”, expected around 2026-04-30.